Please ensure Javascript is enabled for purposes of website accessibility

Why You Should Watch Ariad Pharmaceuticals, Cigna Corporation and Shire plc Today

By George Budwell – Feb 7, 2014 at 8:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Today's biggest stories in healthcare and biotech.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Good morning, fellow Foolish investors! It's time to check in on the top stories in the health care sector this morning.

Sarissa reportedly pushing for board seats at Ariad?
As has become custom of late, Ariad Pharmaceuticals (NASDAQ: ARIA) is moving upwards in premarket trading based on rumors. Specifically, the company's shares are up 7.45% with over 1.4 million shares exchanging hands in extended hours trading, at the time of writing this article.

Today's action is apparently linked to a Reuter's blog stating that Sarissa Capital Management is seeking seats on Ariad's board prior to the upcoming election on Feb. 20, much in the same way they did after taking a big stake in VIVUS Corporation last year. If you recall, Sarissa Capital and First Manhattan shook up VIVUS's board in 2013 in an attempt to right the ship so to speak. 

If this report turns out to be true, however, I don't view it necessarily as a good thing. Sarissa's involvement in VIVUS has not changed the fortunes of the company in the least, and instead, has led to instability within the executive management. In my experience, activist investors tend to cause more harm than good, and it's important to keep in mind that Ariad doesn't have a managerial problem; it has a drug with safety issues problem. Then again, this could turn out to be yet another baseless rumor swirling around Ariad. So, stay tuned!

Cigna's earnings disappoint
Continuing the parade of earnings in the health care sector, Cigna Corporation (CI) reported this morning, missing earnings per share estimates by $0.10, but beating on revenues by a hefty $850 million. Investors shouldn't be too down on the company this morning, however, because the earnings release was generally positive. Annual revenues increased by 11% to $32.4 billion, and Cigna increased earnings per share for the year by a stately 13%.

Turning to the miss, Cigna's earnings missed estimates largely because of a $40 million special charge after taxes due to a restructuring program instituted by the company. Given that this is not expected to be a reoccurring event and instead a one time charge, I think investors would be wise to focus on the broader picture that is emerging, namely strong annual growth that will continue into 2014. The reorganization should also help falling operating margins, which hurt the company's fourth quarter performance. In sum, you might want to dig deeper into this diversified health care company. 

Shire is bummed over late-stage clinical trial results
Shares of Irish biopharma Shire (NASDAQ: SHPG) are down only slightly in premarket trading this morning after the company's experimental drug Vyvanse for major depressive disorder, or MDD, failed to meet its primary endpoints in two late-stage studies. Specifically, the studies showed that while Vyvanse is generally safe, it does not perform better than placebo at reducing symptoms associated with MDD. Because the effectiveness of Vyvanse and placebo were relatively similar at treating MDD, Shire has decided to discontinue the drug's clinical development for this indication altogether. Vyvanse is approved in the U.S. as a treatment for ADHD; so, these two studies were aimed at expanding the drug's current label. 

Although negative clinical trial results are always disappointing, they are an integral part of investing in this sector. On the bright side, large biopharmas like Shire do offer investors strong commercial portfolios that help to soften the blow when these inevitable events occur. Put simply, I don't expect Vyvanse's recent clinical failure to be a major issue going forward. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cigna Corp. Stock Quote
Cigna Corp.
CI

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.